Related Experiment Video
Updated: Feb 3, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Developing combination immunotherapies against cancer that make sense
André Veillette1,2,3, Dominique Davidson4
1Laboratory of Molecular Oncology, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec H2W1R7, Canada. andre.veillette@ircm.qc.ca.
Combination immunotherapies targeting programmed cell death protein 1 (PD-1) and Glucocorticoid-induced tumor necrosis factor receptor (GITR) may synergize. Preclinical data suggest this approach could be effective for treating human cancers.
Area of Science:
- Immunology
- Oncology
- Preclinical Cancer Research
Background:
- Cancer immunotherapy has revolutionized treatment.
- Targeting immune checkpoints like PD-1 is a validated strategy.
- Novel combinations are needed to overcome resistance and improve efficacy.
Purpose of the Study:
- To investigate the potential synergistic effects of combining PD-1 and GITR pathway inhibition.
- To provide a mechanistic rationale for this combination in human cancer.
Main Methods:
- Mechanistic preclinical studies were conducted.
- The studies focused on the interplay between PD-1 and GITR signaling pathways.
Main Results:
- Preclinical data strongly support the hypothesis of synergy.
- The combination of PD-1 and GITR targeting shows promise.
Conclusions:
- Combination immunotherapy targeting PD-1 and GITR warrants further investigation in human cancer.
- This approach may offer enhanced anti-tumor responses.
Related Concept Videos
Tumor Immunotherapy
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Introduction to Special Senses
Tactile and Chemical Senses
Gene Regulation in Microbial Communities: Quorum Sensing
Sustainable Development

